Publication
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (9)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 9
- cancerLung Non-Small Cell Carcinomacivic_curation1.00
- cancerThyroid Gland Medullary Carcinomacivic_curation1.00
- drugSelpercatinibcivic_curation1.00
- geneRETcivic_curation1.00
- variantRET Fusioncivic_curation1.00
- variantRET G810Ccivic_curation1.00
- variantRET G810Rcivic_curation1.00
- variantRET G810Scivic_curation1.00
- variantRET M918Tcivic_curation1.00
Curated evidence
Evidence citing this paper (3)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 31988000
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| RET Fusion + RET G810C + RET G810R + RET G810S1 | ||||||||
| Selpercatinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Resistance | 4 | accepted | EID8195A 61-year old patient with KIF5B-RET fusion positive NSCLC received clinical benefit from selpercatinib treatment initially. ctDNA surveillance showed the emergence of RET G810S 3 months after the sta… (full text at CIViC) PMID 31988000 · Solomon et al., 2020 · Open in CIViC | civic |
| RET Fusion + RET G810S1 | ||||||||
| Selpercatinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Resistance | 4 | submitted | EID12496A RET fusion-positive NSCLC patient who had been treated with multiple lines of chemotherapy and targeted therapies received selpercatinib. The patient initially tolerated selpercatinib achieving a sy… (full text at CIViC) PMID 31988000 · Solomon et al., 2020 · Open in CIViC | civic |
| RET G810S + RET M918T1 | ||||||||
| Selpercatinib | Thyroid Gland Medullary CarcinomaALIAS | Predictive | C | Supports Resistance | 3 | accepted | EID8196In two out of three patients with MTC treated in a phase1/2 trial, the RET G810 mutation emerged in ctDNA together with an acquired resistance after initial response to selpercatinib. PMID 31988000 · Solomon et al., 2020 · Open in CIViC | civic |